跳至主要内容
临床试验/DRKS00024369
DRKS00024369招募中不适用

Database - Esophageal- and Gastric Surgery

niversitätsklinikum Freiburg0 个研究点目标入组 1,500 人开始时间: 2021年7月16日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
1,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Esophageal Surgery or Gastric Surgery (except Bariatric Surgey)

排除标准

  • 未提供

研究者

相似试验

已完成
不适用
Resection of esophageal, gastric, duodenal and colorectal neoplasias by ESD – Learning curve in a prevalence-based unsupervised western setting: a retrospective, multicentric trialBenign neoplasm esophagus, stomach, duodenum, colon or rectum.Malignant neoplasm esophagus, stomach, duodenum, colon and rectum.
DRKS00025012Ev. Diakoniekrankenhaus Freiburg480
尚未招募
不适用
Esophagectomy for patients with resectable esophageal cancer and cervical lymph node metastasesCervical lymph node metastasisEsophageal cancer
NL-OMON24304niversity Medical Center Utrecht20
进行中(未招募)
不适用
Healing of patients suffering from gastroesophageal reflux esophagitisgrade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeks - Magnum IIGastroesophageal reflux esophagitisMedDRA version: 5.0Level: lltClassification code 10038263
EUCTR2004-000492-33-LTALTANA Pharma AG800
进行中(未招募)
不适用
Healing of patients suffering from gastroesophageal reflux esophagitisgrade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeks
EUCTR2004-000492-33-LVALTANA Pharma AG800
进行中(未招募)
不适用
Healing of patients suffering from gastroesophageal reflux esophagitisgrade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeksGastroesophageal reflux esophagitisMedDRA version: 5.0Level: lltClassification code 10038263
EUCTR2004-000493-32-ATALTANA Pharma AG1,980